# Aurora Cannabis Inc. (ACB) Stock Analysis: Exploring a 66.60% Potential Upside

- Link: https://www.directorstalkinterviews.com/aurora-cannabis-inc-acb-stock-analysis-exploring-a-66-60-potential-upside/4121241670
- Published: 2026-02-26T11:27:53+00:00
- Author: Madison Wilson

Aurora Cannabis Inc. (NASDAQ: ACB) is capturing investor attention with its potential
upside of 66.60%, as highlighted by recent analyst ratings. As a key player in the
healthcare sector, specifically in the drug manufacturing industry focusing on specialty
and generic products, Aurora Cannabis is strategically positioned in the burgeoning
cannabis market. Headquartered in Edmonton, Canada, the company has an impressive
reach, distributing pharmaceutical-grade cannabis products both domestically and
internationally.

The company currently trades at $3.83, marking a modest price change of 0.01% recently.
Over the past year, its stock price has fluctuated between $3.31 and $6.23, and 
with an average target price set at $6.38 by analysts, the potential for a significant
price increase seems feasible. This optimism is reflected in the analyst ratings,
with three recommending a ‘buy’ and two suggesting a ‘hold.’ Notably, there are 
no sell ratings, indicating a generally positive sentiment towards the stock.

Aurora’s revenue growth of 6.80% signals a capacity for expansion, although the 
company faces challenges, as evidenced by its negative EPS of -1.09 and a return
on equity of -15.51%. These figures suggest that while revenue is increasing, profitability
remains elusive. However, Aurora’s free cash flow of approximately $11.86 million
provides a cushion for its operations and potential investments in growth initiatives.

The technical indicators present a mixed picture. The stock’s 50-day and 200-day
moving averages are $4.21 and $4.77, respectively, indicating that the current price
is trading below both averages. This might suggest a bearish trend. Furthermore,
an RSI of 20.72 indicates that the stock is oversold, which could present a buying
opportunity for contrarian investors. The MACD of -0.13, below its signal line of-
0.18, further corroborates the bearish sentiment, yet these indicators can often
precede a reversal.

Aurora Cannabis also boasts a diverse product portfolio, ranging from dried cannabis
and oils to edibles and concentrates, catering to both medical and consumer markets.
This diversity is complemented by a rich brand portfolio, including San Rafael ’
71 and MedReleaf, which enhances its market presence and consumer reach.

Despite the nonexistence of a dividend yield, which might deter income-focused investors,
Aurora’s zero payout ratio allows it to reinvest all earnings back into the company,
potentially driving future growth. The lack of current profitability metrics like
P/E or PEG ratios further underscores the growth-centric nature of the company.

Investors considering Aurora Cannabis should weigh the potential for significant
capital appreciation against the backdrop of current financial challenges and market
conditions. With the cannabis industry continuing its maturation process, Aurora’s
strategic initiatives and product innovations could pave the way for long-term growth,
making it a compelling consideration for those with a tolerance for volatility and
an eye on future potential.

Share on: